Plain-English translation of NCT05564949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a classic ketogenic diet — a special high-fat, low-carbohydrate eating plan — can help improve outcomes for people with aggressive brain tumors (called high-grade gliomas) or cancer that has spread to the brain. The diet works by changing how your body uses energy, which may slow tumor growth. Researchers will follow participants for three months to see if this dietary approach, combined with standard cancer treatment, helps people live longer.
Recent research suggests that reducing sugar and changing how the body processes glucose might help fight certain cancers. However, there isn't much evidence yet from real patients about whether this diet actually works in clinical practice. This trial aims to fill that gap by carefully testing whether the treatment can extend survival in people with these serious brain tumors.
You likely qualify if…
You likely don't qualify if…
You would follow a special high-fat, low-carbohydrate diet for three months, with possible extension if you're doing well and staying committed. A hospital dietician will adjust the diet specifically for your body's needs to help your body enter a state called ketosis. During the study, you'll likely have regular check-ins to monitor how well you're tolerating the diet and how you're responding, and researchers will compare your outcomes to similar patients' historical records to see if the diet helps you live longer.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Greece
Sponsor
Attikon Hospital
Enrollment target
~15 participants
Started
September 2022
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Arezina N. Kasti, RD
UNIVERSITY GENERAL HOSPITAL ATTIKON
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.